Ucciferri C, Falasca K, Mancino P, Pizzigallo E, Vecchiet J
Infectious Disease Clinic, Department of Medicine and Science of Aging G. d'Annunzio University, School of Medicine, Chieti, Italy.
Infez Med. 2011 Jun;19(2):125-7.
Kidney disease remains a major comorbidity of HIV infection especially in subjects of African ethnicity. HIV-associated renal disease with overt proteinuria has been associated with poorer outcomes and increased mortality. Telmisartan, an angiotensin II receptor blocker partial agonist of the PPAR-? approved for the treatment of hypertension, seems to exert a nephro-protective effect independent of blood pressure reduction in the general population. But data are lacking in HIV-positive patients with proteinuria. A case is described of an HIV-positive African patient with severe proteinuria treated with telmisartan. This therapy allowed proteinuria to be improved. This case shows for the first time that therapy with telmisartan has renoprotective effects also in an African HIV-infected patient.
肾脏疾病仍然是艾滋病毒感染的主要合并症，尤其是在非洲裔人群中。伴有明显蛋白尿的艾滋病毒相关肾病与较差的预后和更高的死亡率相关。替米沙坦是一种血管紧张素II受体阻滞剂，也是PPAR-γ的部分激动剂，已被批准用于治疗高血压，在普通人群中似乎能发挥独立于血压降低之外的肾脏保护作用。但在艾滋病毒阳性且有蛋白尿的患者中缺乏相关数据。本文描述了一例接受替米沙坦治疗的艾滋病毒阳性非洲严重蛋白尿患者。该治疗使蛋白尿得到改善。该病例首次表明，替米沙坦治疗对非洲艾滋病毒感染患者也有肾脏保护作用。
